Biotech and Pharmaceuticals
Walgreens to help bring cell and gene therapies to patients as it expands specialty pharmacy services
A person rides past a Walgreens truck, owned by the Walgreens Boots Alliance, in Manhattan, New York City, on Nov. 26, 2021. Andrew Kelly | Reuters Walgreens on Thursday said it will start to work directly with drugmakers to bring cell and gene therapies to U.S. patients as part of a broader expansion of its specialty […]
Read More
Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
The anti-diabetic medicine “Ozempic” (semaglutide) built by Danish pharmaceutical corporation Novo Nordisk. Joel Saget | AFP | Getty Illustrations or photos The U.S. Senate has launched an investigation into the high rate of Novo Nordisk‘s preferred fat decline and diabetes drugs Ozempic and Wegovy in the United States. The investigation into the Danish drugmaker was […]
Read More
Biogen tops profit estimates as cost cuts take hold, Alzheimer’s drug Leqembi launch picks up
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday reported first-quarter profit that topped estimates as the company’s cost-cutting efforts took hold and sales of its closely watched Alzheimer’s drug, Leqembi, came in higher than expected. Biogen and […]
Read More
More than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says
More than 3 million people with Medicare could be eligible for coverage of Wegovy now that the blockbuster weight loss drug is also approved in the U.S. for heart health, according to an analysis released Wednesday by health policy research organization KFF. But some eligible beneficiaries could still face out-of-pocket costs for the highly popular […]
Read More
Swiss pharma giant Roche’s to start with-quarter sales edge bigger as its emerges from put up-Covid-19 slump
A logo at the Roche Keeping AG headquarters in Basel, Switzerland, on Thursday, Feb. 1, 2024. Bloomberg | Getty Visuals Swiss pharmaceutical firm Roche on Wednesday documented a modest uptick in to start with-quarter income, even as waning demand for its Covid-19 items continued to weigh on the company. Revenue were up 2% at continuous […]
Read More
Healthy Returns: Biotech IPOs ramped up to start 2024, but the market hasn’t fully recovered just yet
Angelp | Istock | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! After a two-year dry spell, initial public offerings by biotech companies showed signs of life during the first three months of 2024. But it’s too early to say that […]
Read More
Drugmaker Novartis climbs 4.4% right after steering rise on product sales of blockbuster prescription drugs
Signage for Novartis AG at a making in the company’s headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023. Bloomberg | Bloomberg | Getty Illustrations or photos Shares of Swiss drugmaker Novartis climbed as a lot as 4.8% in early specials on Tuesday, right after the firm elevated its entire-year steering next much better-than-anticipated […]
Read More
Most people on weight loss drugs are spending less on restaurants and takeout, survey says
A food delivery messenger carries a take out bag outside aSweetgreen in Manhattan on September 14, 2023. Jeenah Moon | The Washington Post | Getty Images A highly popular group of weight loss and diabetes drugs is decreasing some consumers’ appetites — and also how much they spend on food. Most people taking those medications, […]
Read More
Most doses of Eli Lilly’s Zepbound, Mounjaro in short supply through June, FDA says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Most doses of Eli Lilly‘s highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according […]
Read More
Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. The […]
Read More